<?xml version="1.0" encoding="UTF-8"?>
<p>The multi-CDKIs 
 <bold>1</bold>–
 <bold>4</bold> exhibited potent anticancer activities against breast, ovarian, and colon cancers which could be attributed to their pan-CDKs inhibitory activities
 <xref rid="CIT0015" ref-type="bibr">
  <sup>15–18</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0057" ref-type="bibr">
  <sup>57</sup>
 </xref>. The ability of these compounds to inhibit multi-CDKs could be attributed to the shared pharmacophoric groups between the four compounds, 
 <xref ref-type="fig" rid="F0001">Figure 1</xref>. In addition, high sequence similarities were confirmed between different members in the CDK family. CDK-6 and CDK-9 have sequence similarity of 44% and 32% with CDK-2, respectively
 <xref rid="CIT0006" ref-type="bibr">
  <sup>6</sup>
 </xref>. These similarities could also allow the CDK-2 inhibitors to target other members in the CDK family.
</p>
